

Date: 24th September, 2024

To,
National Stock Exchange of India Ltd.,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E),
Mumbai - 400 051

Stock Code: VAISHALI

Sub: Press Release: Vaishali Pharma Embarks on Ambitious Growth Strategy:
Plans Strategic Merger and Acquisition to Deepen Roots, Expand Product
Portfolio, and Strengthen Position in Global Pharmaceutical Market

Dear Sir/ Madam,

Pursuant to Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 please find enclosed the press release on the captioned subject being issued today.

Kindly take the above information on your records.

Thanking You,
Yours Faithfully,

For Vaishali Pharma Limited

Atul Arvind Vasani
Managing Director

Encl: As above

MEDIA RELEASE

Vaishali Pharma Embarks on Ambitious Growth Strategy: Plans Strategic Merger and Acquisition to Deepen Roots, Expand Product Portfolio, and Strengthen Position in Global Pharmaceutical Market

Mumbai, September 24, 2024, Vaishali Pharma Limited Plans Strategic Merger and Acquisition to Deepen Roots, Expand Product Portfolio, and Strengthen Position in Global Pharmaceutical Market. Vaishali Pharma's announcement to explore strategic mergers and amalgamations signals a proactive approach to enhancing its operational capacity and market reach. The upcoming board meeting on October 03, 2024, will likely be a key moment where the company further discusses these moves, shedding light on their strategic direction and future growth plans. This focus on consolidation could help them strengthen their position in the competitive pharmaceutical industry, potentially driving expansion and improving efficiencies.

Vaishali Pharma Ltd. is a reputable pharmaceutical company with a strong presence in Pharmaceutical business. Established in 1989, Vaishali Pharma Limited specializes in the production and marketing of a diverse range of pharmaceutical products, including APIs, formulations, surgical products, veterinary supplements, herbal items, nutraceuticals, and oncology products. Their portfolio serves both human and animal healthcare needs. The company has over 250 + formulation brands marketed in multiple countries and a robust pipeline of around 250 Dossiers. The company's synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with clients. Company is one of the fastest-growing and most versatile company in the pharmaceutical industry. It has a strong presence in both the domestic and export markets and is currently supplying to all leading Indian and international companies.



As an emerging force, Vaishali Pharma is poised to contribute substantially to the pharmaceutical landscape in India. The company had recently announced the launch of its new brand "HealthE" for local online market. The first product in this lineup is HealthE Biotin and Multivitamin Gummies is a revolutionary product designed to

enhance hair, skin, and overall health. These delectable gummies combine the power of biotin, essential vitamins, and natural extracts to support hair growth, promote radiant skin, and boost overall vitality. All the products launched are backed by food scientist. This exciting development is a testament to the company's ongoing commitment to delivering health and wellness solutions that improve lives and promote lasting well-being. The company plans to add many more products in near future.

"Our venture into the Nutraceutical Products segment, in addition to our ongoing collaborations and alliances, is poised to serve as pivotal growth catalysts in the future. We eagerly anticipate the continuation of our journey towards excellence, with the utmost focus on delivering value to our stakeholders and making significant contributions to the enhancement of healthcare worldwide. Our unwavering dedication to innovation, commitment to maintaining high-quality standards, and the strategic expansion of our global footprint through valuable partnerships have been instrumental in driving our success", added **Mr. Vasani**.

With a vision "To be a well-recognised Indian MNC in the pharmaceuticals and healthcare industry", the company continue to work on its mission to contribute substantially towards well-being and health of the society by providing high quality products and service.

For more details please visit: www.vaishalipharma.com

For any Investor Relations query, please contact:

Mr. Ratnesh Singh
Chief Financial Officer
Email: investor@vaishalipharma.com , cs@vaishalipharma.com

Note: Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.